Internal Medicine, Rheumatology · Seattle, WA
NPI
1972745230
Since 2009
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
10330 Meridian Ave N, Suite 250
Seattle, WA, 98133
Phone (206) 368-6123
Groups this clinician bills Medicare through
Medicare paid, 2024
$498K
33,381 services
Medicare patients, 2024
323
Average age 73
Drug cost, 2024
$1.7M
1,838 prescriptions
Company payments
-
None reported
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Philip E Moberg was code J1602 (injection, golimumab, 1 mg, for intravenous use), 10,189 times for 30 patients. In total Philip E Moberg billed 33,381 services in 41 codes, and Medicare paid $498K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2010-11-01.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 10,189 | 30 | $9.06 | $92K |
| J3262 Injection, tocilizumab, 1 mg | Office | 9,206 | 11 | $4.66 | $43K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 3,675 | 29 | $33.29 | $122K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 2,380 | 25 | $24.85 | $59K |
| 99214 Office E&M - Established | Office | 376 | 174 | $76.21 | $29K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 348 | 170 | $14.17 | $4,931 |
| 96365 Intravenous Infusion, Hydration | Office | 185 | 120 | $60.27 | $11K |
| J3489 Injection, zoledronic acid, 1 mg | Office | 110 | 22 | $4.67 | $514 |
| J7050 Infusion, normal saline solution, 250 cc | Office | 68 | 45 | $0.52 | $35.05 |
| 96413 Chemotherapy Administration | Office | 59 | 40 | $124.10 | $7,322 |
| 99213 Office E&M - Established | Office | 39 | 34 | $41.85 | $1,632 |
| 99215 Office E&M - Established | Office | 34 | 25 | $120.78 | $4,107 |
| 96415 Chemotherapy Administration | Office | 31 | 15 | $26.16 | $811 |
| 96375 Injection Administration | Office | 21 | 19 | $14.10 | $296 |
| 20610 Joint Injection | Office | 18 | 12 | $36.88 | $664 |
By year: 2022 $529K for 32,605 services; 2023 $526K for 26,956 services; 2024 $498K for 33,381 services.
Lab tests billed to Medicare, 2023
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 14 | 14 | $8.40 | $118 |
Medicare prescription drug claims, 2024
In 2024, the drug Philip E Moberg prescribed most often to Medicare patients was Methotrexate (Methotrexate Sodium), with 267 prescriptions and refills. In total Philip E Moberg wrote 1,838 Medicare prescriptions that cost $1.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Methotrexate Methotrexate Sodium | 267 | 496 | 58 | $6,501 |
| Hydroxychloroquine Sulfate Generic | 175 | 389 | 40 | $7,871 |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 128 | 128 | 19 | $2,891 |
| Prednisone Generic | 109 | 171 | 31 | $1,375 |
| Sulfasalazine Generic | 94 | 174 | 25 | $2,939 |
| Allopurinol Generic | 83 | 227 | 19 | $1,260 |
| Leflunomide Generic | 83 | 174 | 22 | $5,552 |
| Tramadol Hcl Generic | 66 | 66 | Under 11 | $475 |
| Folic Acid Generic | 62 | 161 | 18 | $710 |
| Oxycodone Hcl Generic | 53 | 53 | Under 11 | $1,157 |
| Gabapentin Generic | 44 | 103 | 11 | $910 |
| Meloxicam Generic | 42 | 94 | 11 | $245 |
| Celecoxib Generic | 35 | 73 | Under 11 | $1,428 |
| Pilocarpine Hcl Generic | 31 | 35 | Under 11 | $1,114 |
| Pregabalin Generic | 28 | 36 | Under 11 | $254 |
Brand drugs: 342 claims; generic drugs: 1,476 claims; opioid claims: 293.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Philip E Moberg were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.